FOXL2 and neoplasm: The primary screen of 752 whole genome amplified tumor DNA samples yielded 24 samples (∼4%) with a variant profile, distinct from that seen in association with the FOXL2 c.402C>G mutation-positive A-GCT specimens, as well as 41 with an indeterminate profile and 29 samples that failed.